Skip to main content
Erschienen in: Tumor Biology 6/2012

01.12.2012 | Research Article

Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma

verfasst von: Takeshi Hanagiri, Shinji Shinohara, Masaru Takenaka, Yoshiki Shigematsu, Manabu Yasuda, Hidehiko Shimokawa, Yoshika Nagata, Makoto Nakagawa, Hidetaka Uramoto, Tomoko So, Fumihiro Tanaka

Erschienen in: Tumor Biology | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Abstract

Hyaluronic acid (HA) has been proposed as a biochemical marker of malignant pleural mesothelioma (MPM). The present study focused on the implications of HA and CD44 interaction in the proliferation and invasiveness of MPM. The proliferation and invasive activity was evaluated in two human mesothelioma cell lines, ACC-MESO-1 and K921MSO, by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and the transwell chamber model. The knockdown of CD44 gene expression was accomplished by transfection of the cells with small interfering RNA. Flow cytometry revealed that both the ACC-MESO-1 and K921MSO cell lines highly expressed CD44. Treatment with HA enhanced the proliferation in both mesothelioma cell lines in comparison to cells without HA treatment. The treatment with HA (25 μg/ml) also significantly upregulated the invasion of both types of cells. The silencing of CD44 significantly abrogated the effect of HA treatment on the proliferation of ACC-MESO-1 cells and significantly suppressed the proliferation of K921MSO cells. HA–CD44 binding is important for the migration and proliferation of mesothelioma cells. Therefore, the HA–CD44 interaction is a potentially useful therapeutic target in MPM.
Literatur
1.
Zurück zum Zitat Peto J, Hodgson JT, Matthews FE, et al. Continuing increase in mesothelioma mortality in Britain. Lancet. 1995;345:535–9.PubMedCrossRef Peto J, Hodgson JT, Matthews FE, et al. Continuing increase in mesothelioma mortality in Britain. Lancet. 1995;345:535–9.PubMedCrossRef
2.
Zurück zum Zitat Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999;79:666–72.PubMedCrossRef Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer. 1999;79:666–72.PubMedCrossRef
3.
Zurück zum Zitat Gemba K, Fujimoto N, Kato K, Aoe K, Takeshima Y, Inai K, et al. National survey of malignant mesothelioma and asbestos exposure in Japan. Cancer Sci. 2012;103:483–90.PubMedCrossRef Gemba K, Fujimoto N, Kato K, Aoe K, Takeshima Y, Inai K, et al. National survey of malignant mesothelioma and asbestos exposure in Japan. Cancer Sci. 2012;103:483–90.PubMedCrossRef
4.
Zurück zum Zitat Murayama T, Takahashi K, Natori Y, Kurumatani N. Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med. 2006;49:1–7.PubMedCrossRef Murayama T, Takahashi K, Natori Y, Kurumatani N. Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med. 2006;49:1–7.PubMedCrossRef
5.
Zurück zum Zitat Marinaccio A, Scarselli A, Binazzi A, et al. Asbestos related diseases in Italy: an integrated approach to identify unexpected professional or environmental exposure risks at municipal level. Int Arch Occup Environ Health. 2008;81:993–1001.PubMedCrossRef Marinaccio A, Scarselli A, Binazzi A, et al. Asbestos related diseases in Italy: an integrated approach to identify unexpected professional or environmental exposure risks at municipal level. Int Arch Occup Environ Health. 2008;81:993–1001.PubMedCrossRef
6.
Zurück zum Zitat Maule MM, Magnani C, Dalmasso P, Mirabelli D, Merletti F, Biggeri A. Modeling mesothelioma risk associated with environmental asbestos exposure. Environ Health Perspect. 2007;115:1066–71.PubMedCrossRef Maule MM, Magnani C, Dalmasso P, Mirabelli D, Merletti F, Biggeri A. Modeling mesothelioma risk associated with environmental asbestos exposure. Environ Health Perspect. 2007;115:1066–71.PubMedCrossRef
7.
Zurück zum Zitat Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.PubMedCrossRef Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.PubMedCrossRef
8.
Zurück zum Zitat Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, et al. Pemetrexed expanded access program investigators. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol. 2006;1:506–12.PubMedCrossRef Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, et al. Pemetrexed expanded access program investigators. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. J Thorac Oncol. 2006;1:506–12.PubMedCrossRef
9.
Zurück zum Zitat Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–63.PubMedCrossRef Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–63.PubMedCrossRef
10.
Zurück zum Zitat Thylén A, Hjerpe A, Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer. 2001;92:1224–30.PubMedCrossRef Thylén A, Hjerpe A, Martensson G. Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer. 2001;92:1224–30.PubMedCrossRef
11.
Zurück zum Zitat Hillerdal G, Lindqvist U, Engström-Laurent A. Hyaluronan in pleural effusions and in serum. Cancer. 1991;67:2410–4.PubMedCrossRef Hillerdal G, Lindqvist U, Engström-Laurent A. Hyaluronan in pleural effusions and in serum. Cancer. 1991;67:2410–4.PubMedCrossRef
12.
13.
Zurück zum Zitat Marhaba R, Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004;35:211–31.PubMedCrossRef Marhaba R, Zöller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004;35:211–31.PubMedCrossRef
14.
Zurück zum Zitat Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama T, Mori S, et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 2006;97:387–94.PubMedCrossRef Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama T, Mori S, et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci. 2006;97:387–94.PubMedCrossRef
15.
Zurück zum Zitat Shigematsu Y, Hanagiri T, Kuroda K, Baba T, Mizukami M, Ichiki Y, et al. Malignant mesothelioma-associated antigens recognized by tumor-infiltrating B cells and the clinical significance of the antibody titers. Cancer Sci. 2009;100:1326–34.PubMedCrossRef Shigematsu Y, Hanagiri T, Kuroda K, Baba T, Mizukami M, Ichiki Y, et al. Malignant mesothelioma-associated antigens recognized by tumor-infiltrating B cells and the clinical significance of the antibody titers. Cancer Sci. 2009;100:1326–34.PubMedCrossRef
16.
Zurück zum Zitat Baas P, Schouwink H, Zoetmulder FA. Malignant pleural mesothelioma. Ann Oncol. 1998;9:139–49.PubMedCrossRef Baas P, Schouwink H, Zoetmulder FA. Malignant pleural mesothelioma. Ann Oncol. 1998;9:139–49.PubMedCrossRef
17.
Zurück zum Zitat Welker L, Müller M, Holz O, Vollmer E, Magnussen H, Jörres RA. Cytological diagnosis of malignant mesothelioma—improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch. 2007;450:455–61.PubMedCrossRef Welker L, Müller M, Holz O, Vollmer E, Magnussen H, Jörres RA. Cytological diagnosis of malignant mesothelioma—improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch. 2007;450:455–61.PubMedCrossRef
18.
Zurück zum Zitat Laurent TC, Laurent UB, Fraser JR. The structure and function of hyaluronan: an overview. Immunol Cell Biol. 1996;74:A1–7.PubMedCrossRef Laurent TC, Laurent UB, Fraser JR. The structure and function of hyaluronan: an overview. Immunol Cell Biol. 1996;74:A1–7.PubMedCrossRef
19.
Zurück zum Zitat Itano N, Sawai T, Atsumi F, Miyaishi O, Taniguchi S, Kannagi R, et al. Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J Biol Chem. 2004;279:18679–87.PubMedCrossRef Itano N, Sawai T, Atsumi F, Miyaishi O, Taniguchi S, Kannagi R, et al. Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J Biol Chem. 2004;279:18679–87.PubMedCrossRef
20.
Zurück zum Zitat Li Y, Li L, Brown TJ, Heldin P. Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. Int J Cancer. 2007;120:2557–67.PubMedCrossRef Li Y, Li L, Brown TJ, Heldin P. Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. Int J Cancer. 2007;120:2557–67.PubMedCrossRef
21.
Zurück zum Zitat Twarock S, Tammi MI, Savani RC, Fischer JW. Hyaluronan stabilizes focal adhesions, filopodia, and the proliferative phenotype in esophageal squamous carcinoma cells. J Biol Chem. 2010;285:23276–84.PubMedCrossRef Twarock S, Tammi MI, Savani RC, Fischer JW. Hyaluronan stabilizes focal adhesions, filopodia, and the proliferative phenotype in esophageal squamous carcinoma cells. J Biol Chem. 2010;285:23276–84.PubMedCrossRef
22.
Zurück zum Zitat Wang SJ, Bourguignon LY. Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance. Am J Pathol. 2011;178:956–63.PubMedCrossRef Wang SJ, Bourguignon LY. Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance. Am J Pathol. 2011;178:956–63.PubMedCrossRef
23.
Zurück zum Zitat Bourguignon LY, Gilad E, Brightman A, Diedrich F, Singleton P. Hyaluronan–CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase Cε–Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells. J Biol Chem. 2006;281:14026–40.PubMedCrossRef Bourguignon LY, Gilad E, Brightman A, Diedrich F, Singleton P. Hyaluronan–CD44 interaction with leukemia-associated RhoGEF and epidermal growth factor receptor promotes Rho/Ras co-activation, phospholipase Cε–Ca2+ signaling, and cytoskeleton modification in head and neck squamous cell carcinoma cells. J Biol Chem. 2006;281:14026–40.PubMedCrossRef
24.
Zurück zum Zitat Stamenkovic I, Yu Q. Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding. J Invest Dermatol. 2009;129:1321–4.PubMedCrossRef Stamenkovic I, Yu Q. Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding. J Invest Dermatol. 2009;129:1321–4.PubMedCrossRef
25.
Zurück zum Zitat Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004;95(12):930–5.PubMedCrossRef Nagano O, Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci. 2004;95(12):930–5.PubMedCrossRef
26.
Zurück zum Zitat Goebeler M, Kaufmann D, Bröcker EB, Klein CE. Migration of highly aggressive melanoma cells on hyaluronic acid is associated with functional changes, increased turnover and shedding of CD44 receptors. J Cell Sci. 1996;109:1957–64.PubMed Goebeler M, Kaufmann D, Bröcker EB, Klein CE. Migration of highly aggressive melanoma cells on hyaluronic acid is associated with functional changes, increased turnover and shedding of CD44 receptors. J Cell Sci. 1996;109:1957–64.PubMed
27.
Zurück zum Zitat Nandi A, Estess P, Siegelman MH. Hyaluronan anchoring and regulation on the surface of vascular endothelial cells is mediated through the functionally active form of CD44. J Biol Chem. 2000;275:14939–48.PubMedCrossRef Nandi A, Estess P, Siegelman MH. Hyaluronan anchoring and regulation on the surface of vascular endothelial cells is mediated through the functionally active form of CD44. J Biol Chem. 2000;275:14939–48.PubMedCrossRef
28.
Zurück zum Zitat Richter U, Wicklein D, Geleff S, Schumacher U. The interaction between CD44 on tumour cells and hyaluronan under physiologic flow conditions: implications for metastasis formation. Histochem Cell Biol. 2012;137:687–95.PubMedCrossRef Richter U, Wicklein D, Geleff S, Schumacher U. The interaction between CD44 on tumour cells and hyaluronan under physiologic flow conditions: implications for metastasis formation. Histochem Cell Biol. 2012;137:687–95.PubMedCrossRef
29.
Zurück zum Zitat Li CZ, Liu B, Wen ZQ, Li HY. Inhibition of CD44 expression by small interfering RNA to suppress the growth and metastasis of ovarian cancer cells in vitro and in vivo. Folia Biol. 2008;54:180–6. Li CZ, Liu B, Wen ZQ, Li HY. Inhibition of CD44 expression by small interfering RNA to suppress the growth and metastasis of ovarian cancer cells in vitro and in vivo. Folia Biol. 2008;54:180–6.
30.
Zurück zum Zitat Sugahara KN, Hirata T, Hayasaka H, Stern R, Murai T, Miyasaka M. Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments. J Biol Chem. 2006;281:5861–8.PubMedCrossRef Sugahara KN, Hirata T, Hayasaka H, Stern R, Murai T, Miyasaka M. Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments. J Biol Chem. 2006;281:5861–8.PubMedCrossRef
31.
Zurück zum Zitat Sohara Y, Ishiguro N, Machida K, Kurata H, Thant AA, Senga T, et al. Hyaluronan activates cell motility of v-Src-Transformed cells via Ras-mitogen-activated protein kinase and phosphoinositide3-kinase-Akt in a tumor-specific manner. Mol Biol Cell. 2001;12:1859–68.PubMed Sohara Y, Ishiguro N, Machida K, Kurata H, Thant AA, Senga T, et al. Hyaluronan activates cell motility of v-Src-Transformed cells via Ras-mitogen-activated protein kinase and phosphoinositide3-kinase-Akt in a tumor-specific manner. Mol Biol Cell. 2001;12:1859–68.PubMed
Metadaten
Titel
Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma
verfasst von
Takeshi Hanagiri
Shinji Shinohara
Masaru Takenaka
Yoshiki Shigematsu
Manabu Yasuda
Hidehiko Shimokawa
Yoshika Nagata
Makoto Nakagawa
Hidetaka Uramoto
Tomoko So
Fumihiro Tanaka
Publikationsdatum
01.12.2012
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2012
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-012-0473-5

Weitere Artikel der Ausgabe 6/2012

Tumor Biology 6/2012 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.